Latest On aTyr Pharma, Inc (LIFE):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-10 04:27 EST | News | aTyr Pharma GAAP EPS of -$0.29 | N/A |  |
| 2023-03-11 01:11 EST | News | aTyr Pharma, Inc. (LIFE) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-09 18:48 EST | News | aTyr Pharma GAAP EPS of -$0.26 beats by $0.22, revenue of $10.4M beats by $10.15M | N/A | |
| 2023-02-09 12:24 EST | News | aTyr Pharma: The Uncertainty Of Efzofitimod, Analysis Of Clinical Study | N/A | |
| 2023-02-09 12:24 EST | News | aTyr Pharma stock dips after pricing $50M stock offering | N/A | |
About aTyr Pharma, Inc (LIFE):
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial. The company has a collaboration with the University of Nebraska Medical Center for the development of NRP2 biology; research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases; and research collaboration with Boston Children's Hospital. It also has license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATY read more...R1923 for ILDs in Japan; and a research collaboration with the Medical University of South Carolina to develop therapeutic antibodies that selectively target specific NRP2 isoforms. The company was founded in 2005 and is headquartered in San Diego, California.
General
- Name aTyr Pharma, Inc
- Symbol LIFE
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 39
- Last Split Factor1:14
- Last Split Date2019-07-01
- Fiscal Year EndDecember
- IPO Date2015-05-07
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.atyrpharma.com
Valuation
- Price/Sales (Trailing 12 Mt.) 4.89
- Price/Book (Most Recent Quarter) 1.78
- Enterprise Value Revenue 3.1
- Enterprise Value EBITDA 0.01
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.69
- Profit Margin -202%
- Operating Margin -198%
- Return on Assets -25%
- Return on Equity -59%
- Revenue 8.55 million
- Earnings Per Share -$10.21
- Revenue Per Share $1.15
- Gross Profit -13626000
- Quarterly Earnings Growth -19.6%
Highlights
- Market Capitalization 53.58 million
- EBITDA -23464000
- PE Ratio -2.37
- Analyst Target Price $15
- Book Value Per Share $3.22
Share Statistics
- Shares Outstanding 10.19 million
- Shares Float 8.42 million
- % Held by Insiders 525%
- % Held by Institutions 64.57%
- Shares Short 297643
- Shares Short Prior Month 159766
- Short Ratio 0.17
- Short % of Float 3%
- Short % of Shares Outstanding 3%
Technicals
- Beta 2.02
- 52 Week High $7.93
- 52 Week Low $2.4
- 50 Day Moving Average 5
- 200 Day Moving Average 4.07
Dividends
- Dividend Date 2019-07-01
- ExDividend Date N/A
- Dividend Yield 0%
aTyr Pharma, Inc (LIFE) Dividend Calendar:
LIFE's last dividend payment was made to shareholders on July 1, 2019.
aTyr Pharma, Inc (LIFE) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
aTyr Pharma, Inc (LIFE) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
aTyr Pharma, Inc (LIFE) Chart:
aTyr Pharma, Inc (LIFE) News:
Below you will find a list of latest news for aTyr Pharma, Inc (LIFE) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
aTyr Pharma, Inc (LIFE) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest LIFE Trades:
aTyr Pharma, Inc (LIFE) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-02 | 424B3 (Prospectus [Rule 424(b)(3)]) | |
| 2020-09-28 | EFFECT (Notice of Effectiveness) | |
| 2020-09-24 | UPLOAD (SEC-generated letter) | |
| 2020-09-24 | CORRESP (Correspondence) | |
| 2020-09-18 | S-1 (General form for registration of securities under the Securities Act of 1933) | |
| 2020-09-14 | 8-K (Current report) | |
| 2020-09-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-28 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-18 | S-8 (Securities to be offered to employees in employee benefit plans) | |
| 2020-08-13 | 8-K (Current report) | |
| 2020-08-13 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-06-23 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-23 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-23 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-22 | 8-K (Current report) | |
| 2020-05-28 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-28 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-28 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-20 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
aTyr Pharma, Inc (LIFE) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of aTyr Pharma, Inc (LIFE). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 525%
Institutional Ownership: 6457%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-02 | JOHN K CLARKE | Director | Sell | 7,260.00 | 4.01 | 29,112.60 | 110,583.00 | |
| 2020-08-28 | JOHN K CLARKE | Director | Sell | 100.00 | 4.00 | 400.00 | 117,843.00 | |
| 2020-08-27 | JOHN K CLARKE | Director | Sell | 5,440.00 | 4.09 | 22,249.60 | 117,943.00 | |
| 2020-08-26 | JOHN K CLARKE | Director | Sell | 2,200.00 | 4.30 | 9,451.20 | 123,383.00 | |
| 2020-06-19 | Sanjay Shukla | President and CEO | Buy | 6,000.00 | 4.27 | 25,620.00 | 7,291.00 | |
| 2020-06-19 | Jill Marie Broadfoot | Chief Financial Officer | Buy | 1,850.00 | 4.22 | 7,807.00 | 9,153.00 | |
| 2020-05-20 | NANCY DENYES | General Counsel | Sell | 322.00 | 3.62 | 1,165.64 | 2,735.00 | |
| 2020-05-20 | PAUL SCHIMMEL | Director | Sell | 8,447.00 | 3.64 | 30,738.63 | 429,143.00 | |
| 2020-05-16 | NANCY DENYES | General Counsel | Buy | 892.00 | 3,057.00 | | ||
| 2020-02-10 | PAUL SCHIMMEL | Director | Buy | 254,000.00 | 4.25 | 1,079,500.00 | 437,590.00 | |
| 2020-02-07 | Sanjay Shukla | President and CEO | Sell | 745.00 | 4.03 | 3,002.35 | 1,291.00 | |
| 2020-02-07 | Jill Marie Broadfoot | Chief Financial Officer | Sell | 375.00 | 4.03 | 1,511.25 | 7,125.00 | |
| 2020-02-06 | Sanjay Shukla | President and CEO | Buy | 1,786.00 | 2,036.00 | | ||
| 2020-02-06 | Jill Marie Broadfoot | Chief Financial Officer | Buy | 893.00 | 7,500.00 | | ||
| 2014-02-03 | BALAKRISHNAN S IYER | Director | Sell | 8,888.00 | 76.13 | 676,654.11 | 0.00 | |
| 2014-02-03 | DAVID C UPRICHARD | Director | Sell | 2,930.00 | 76.13 | 223,064.42 | 0.00 | |
| 2014-02-03 | David F Hoffmeister | Chief Financial Officer | Sell | 84,804.00 | 76.13 | 6,456,230.28 | 0.00 | |
| 2014-02-03 | GEORGE F JR ADAM | Director | Sell | 2,747.00 | 76.13 | 209,132.41 | 0.00 | |
| 2014-02-03 | GREGORY T LUCIER | Chief Executive Officer | Sell | 456,046.00 | 76.13 | 34,719,329.24 | 0.00 | |
| 2014-02-03 | JOHN A COTTINGHAM | Chief Legal Officer | Sell | 8,231.00 | 76.13 | 626,635.91 | 0.00 | |